^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

Published date:
05/07/2021
Excerpt:
This is a single institution, open-label, phase I dose-escalation study in patients with advanced malignancies (NCT 01548144)....Among other patients with PR as best response to therapy, we had a clear cell renal cancer patient (−32%, PR) with a Kinase Insert Domain Receptor (KDR) p.C482R mutation previously treated with multiple lines of therapy including pazopanib monotherapy for a year (best response on monotherapy was SD).
DOI:
10.2147/OTT.S291801
Trial ID: